Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions

Experimental Neurology

Volumn 171, Issue 2, 2001, Pages 405-417

  Carvalho, Gustavo A ^a   Nikkhah, Guido ^a  

^a NORDSTADT HOSPITAL   (Germany)

Author keywords

Basal ganglia; Dopamine; Nigrostriatal pathway; Rat; Retrograde degeneration; Sensorimotor behavior

Indexed keywords

GLUTAMATE RECEPTOR; IBOTENIC ACID; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY POSTURE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; STEREOLOGY; STRIATONIGRAL DEGENERATION; SUBTHALAMIC NUCLEUS;

EID: 0034800339     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2001.7742     Document Type: Article

References (42)

1. Differential effect of subthalamic nucleus ablation on dopamine D-1 and D-2 agonist-induced rotation in 6-hydroxydopamine-lesioned rats
2. Future prospects of brain stimulation
3. Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson's disease
4. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus
5. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease
6. Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats
7. Functional changes of the basal ganglia circuitry in Parkinson's disease
8. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen
9. Depletion of unilateral striatal dopamine impairs initiation of contralateral actions but not sensory attention
10. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death
11. Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease
12. The functional role of mesotelencephalic dopamine systems
13. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
14. Pathogenesis and preclinical course of Parkinson's disease
15. Functional neuropathology in Parkinson's disease
16. Some new, simple, and efficient stereological methods and their use in pathological research and diagnosis
17. Subthalamic nucleus lesions induce deficits as well as benefits in the hemiparkinsonian rat
18. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: Evidence for cell death in the substantia nigra
19. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
20. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system
21. Efferent projections of the subthalamic nucleus in the rat: Light and electron microscopic analysis with the PHA-L method
22. The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease
23. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
24. The staircase test': A measure of independent forelimb reaching and grasping abilities in rats
25. Substantia nigra pars reticulata single unit activity in normal and 6OHDA-lesioned rats: Effects of intrastriatal apomorphine and subthalamic lesions
26. Differences in acquisition and full performance in skilled forelimb use as measured by the 'staircase test' in five rat strains
27. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced
28. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test
29. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: A stereological study using the cavalieri and optical disector methods
30. Reaction time performance following unilateral striatal dopamine depletion and lesions of the subthalamic nucleus in the rat
31. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: Behavioural and immunohistochemical studies
32. Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease
33. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine
34. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection
35. Complex sensorimotor behavioral changes after terminal striatal 6-OHDA lesion and transplantation of dopaminergic embryonic micrografts
36. Comparison of uni- versus bilateral intrastriatal 6-OHDA-induced axon terminal lesions: Evidence for interhemispheric functional coupling of the two nigrostriatal pathways
37. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model
38. Progressive degeneration of nigrostriatal dopamine neurons following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat
39. A clinically relevant unilateral rat model of Parkinsonian akinesia
40. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopamine neurons in a rat model of Parkinson's disease
41. Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants